The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Ryan Louvar, Chief Policy Officer and Head of Business and Legal Affairs, Digital Assets at WisdomTree, breaks down the CLARITY Act and crypto’s next phase.
KFC U.S. President Catherine Tan-Gillespie breaks down Open House, the new hospitality-first concept meant to reinvent the Colonel for today's consumers.
New Crunch Fitness CEO Chequan Lewis discusses Crunch 3.0, blending boutique fitness, recovery wellness and digital training into an accessible gym model.
